QUANTERIX CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.97 USD | -2.14% |
|
-2.74% | -41.59% |
| May. 08 | Transcript : Quanterix Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 07 | Quanterix Corporation Announces Resignation of Brian J. Blaser from its Board of Directors | CI |
Financials (USD)
| Sales 2024 * | 142M | Sales 2025 * | 169M | Capitalization | 611M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -33M | EV / Sales 2024 * | 4.08 x |
| Net cash position 2024 * | 31.83M | Net cash position 2025 * | 33.4M | EV / Sales 2025 * | 3.43 x |
| P/E ratio 2024 * |
-16.8
x | P/E ratio 2025 * |
-18.9
x | Employees | 441 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quanterix Corporation
More recommendations
More press releases
More news
| 1 day | -2.14% | ||
| 1 week | -2.74% | ||
| 1 month | -0.93% | ||
| 3 months | -33.35% | ||
| 6 months | -33.38% | ||
| Current year | -41.59% |
1 week
15.85
17.08
1 month
14.2618.17
Current year
14.2629.70
1 year
14.2629.70
3 years
6.3169.22
5 years
6.3192.57
10 years
6.3192.57
| Managers | Title | Age | Since |
|---|---|---|---|
Masoud Toloue
CEO | Chief Executive Officer | 43 | 21-06-08 |
Vandana Sriram
DFI | Director of Finance/CFO | 50 | 23-08-20 |
Martin Madaus
CHM | Chairman | 64 | 10-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Madaus
CHM | Chairman | 64 | 10-10-31 |
| Director/Board Member | 59 | 19-07-24 | |
Laurie Olson
BRD | Director/Board Member | 61 | 21-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.30% | 12 M€ | -.--% | - | |
| 0.09% | 2 M€ | -.--% | ||
| 0.05% | 7 M€ | -.--% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 15.97 | -2.14% | 375,349 |
| 24-05-30 | 16.32 | +0.87% | 325,303 |
| 24-05-29 | 16.18 | -2.06% | 358,359 |
| 24-05-28 | 16.52 | +0.61% | 274,425 |
| 24-05-24 | 16.42 | -0.85% | 217,847 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Calendar
2024-06-03
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.97
USD
Average target price
28.4
USD
Spread / Average Target
+77.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.59% | 611M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
- Stock Market
- Equities
- QTRX Stock
